CJC-1295 vs Sermorelin: Growth Hormone Secretagogue Kinetics
Analyzing half-life, pulse amplification, and pituitary signaling between GHRH analogs.
CJC-1295
GHRH Analog (No DAC)
A tetrasubstituted GHRH analog with four amino acid substitutions that increase receptor affinity and proteolytic resistance. Most commonly studied in combination with Ipamorelin for synergistic GH pulse amplification.
Sermorelin
GHRH (1-29) Analog
A synthetic 29-amino-acid fragment of growth hormone-releasing hormone (GHRH 1-29), FDA-approved as a diagnostic agent for GH deficiency. Stimulates the pituitary to release endogenous growth hormone.
Executive Research Summary
CJC-1295 (Modified GRF 1-29) and Sermorelin (GHRH 1-29) are both synthetic analogs of human growth hormone-releasing hormone. Sermorelin represents the first-generation 29-amino-acid active core, characterized by a rapid 12-minute half-life. CJC-1295 incorporates amino acid substitutions that resist enzymatic cleavage (DPP-4), extending its active half-life and providing stronger GH pulse amplification.
Key Differentiating Factors
Half-Life: Sermorelin has an in vivo half-life of ~10–12 minutes; CJC-1295 (no DAC / Mod GRF 1-29) lasts ~30 minutes; CJC-1295 with DAC lasts ~6–8 days.
Enzymatic Stability: CJC-1295 contains 4 substituted amino acids (D-Ala, Gln, Ala, Leu) that protect it from rapid breakdown by dipeptidyl peptidase-4.
Regulatory History: Sermorelin is FDA-approved (Geref) as a diagnostic agent; CJC-1295 is an investigational research peptide.
Pulsatility: CJC-1295 (no DAC) and Sermorelin preserve natural physiological GH pulsatility when paired with a GHRP like Ipamorelin.
Head-to-Head Specification Matrix
| Comparison Metric | CJC-1295 | Sermorelin |
|---|---|---|
| Molecular Stability | High (engineered with 4 amino acid substitutions against DPP-4) Advantage | Low (native sequence rapidly degraded by blood enzymes) |
| FDA Approval & Clinical Track Record | Investigational research compound | FDA-approved diagnostic drug (Geref) Advantage |
| GH Pulse Amplification Strength | Significantly higher peak GH release per equivalent microgram dose Advantage | Moderate GH pulse amplification |
Head-to-Head Research Verdict
Choose CJC-1295 If:
Protocols targeting maximum GH and IGF-1 elevation with lower dose frequency requirements.
Choose Sermorelin If:
Protocols requiring a clinical reference standard with established FDA regulatory documentation.
Bottom Line: CJC-1295 (specifically Mod GRF 1-29 without DAC) has largely superseded Sermorelin in modern research due to superior enzymatic stability and GH release amplitude.